Targeted radiotherapies maximize cytotoxicty to cancer cells. In vivo α-generator targeted radiotherapies can deliver multiple α particles to a receptor site dramatically amplifying the radiation dose delivered to the target. The major challenge with α-generator radiotherapies is that traditional chelating moieties are unable to sequester the radioactive daughters in the bioconjugate which is critical to minimize toxicity to healthy, non-target tissue. The recoil energy of the 225Ac daughters following α decay will sever any metal-ligand bond used to form the bioconjugate. This work demonstrates that an engineered multilayered nanoparticle-antibody conjugate can deliver multiple α radiations and contain the decay daughters of 225Ac while targeting biologically relevant receptors in a female BALB/c mouse model. These multi-shell nanoparticles combine the radiation resistance of lanthanide phosphate to contain 225Ac and its radioactive decay daughters, the magnetic properties of gadolinium phosphate for easy separation, and established gold chemistry for attachment of targeting moieties.
References
[1]
Jacene HA, Filice R, Kasecamp W (2007) Wahl (2007) Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J. Nucl. Med. 48: 1767–76.
[2]
Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 3: 488–99.
[3]
(2011) Melphalan with or without Holmium Ho-166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients with Multiple Myeloma. Available: http://clinicaltrials.gov/ct2/show/NCT00？008229?term=Ho166&phase=2&rank=1. Accessed 2011 Nov 1.
[4]
(2011) Chemotherapy with or without Strontium-89 in Treating Patients with Prostate Cancer. Available: http://clinicaltrials.gov/ct2/show/NCT00？024167?term=Sr89&phase=2&rank=1. Accessed 2011 Nov 1.
[5]
Humm JL (1986) Dosimetric aspects of radiolabeled antibodies for tumor-therapy. J. Nucl. Med. 27: 1490–7.
[6]
Zalutsky MR, Pozzi OR (2004) Radioimmunotherapy with alpha-particle emitting radionuclides. Q. J. Nucl. Ned. Mol. Imaging 48: 289–96.
[7]
Kampf G (1988) Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol. Radiother. 29: 631–58.
[8]
Hall EJ, Giaccia A (2006) Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 546 p.
[9]
Gadbois DM, Crissman HA, Nastasi A, Habbersett R, Wang SK, et al. (1996) Alterations in the progression of cells through the cell cycle after exposure to alpha particles or gamma rays. Radiat. Res. 146: 414–24.
[10]
Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted α-particle therapy. J. Nucl. Med. 46 (Suppl 1)199S–204S.
[11]
Kim Y, Brechbiel MW (2012) An overview of targeted alpha therapy. Tumor Biol. 33: 573–90.
[12]
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, et al. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294: 1537–40.
[13]
Schwartz J, Jaggi JS, O’Donoghue JA, Ruan S, McDevitt M, et al. (2011) Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys. Med. Biol. 56: 721–733.
[14]
Essler M, G？rtner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, et al. (2012) Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical muse model of peritoneal carcinomatosis. Eur. J Nucl. Med. Mol. Imaging 39: 602–612.
[15]
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, et al. (2009) Radioimmunotherapy of breast cancer metastases with α-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y. Cancer Res. 69: 8941–8948.
[16]
Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G (2004) Engineered liposomes for potential α-particle therapy of metastatic cancer. J. Nucl. Med. 45: 253–60.
[17]
Bruland OS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12: 6250s–7s.
[18]
(2011) FDA Grants Fast Track Designation For Alpharadin For Castration Resistant Prostate Cancer In Patients With Bone Metastases. Available: http://www.medicalnewstoday.com/articles？/233215.php. Accessed 2012 Aug 18.
[19]
Tabuteau A, Pages M, Livet J, Musikas C (1988) Monazite-like phases containing transuranium elements (neptunium and plutonium). J. Mater. Sci. Lett. 7: 1315–7.
[20]
Ewing RC (1975) Am. Mineral. (1975) Crystal chemistry of complex niobium and tantalum oxides. 60: 728–33.
[21]
Karioris FG, Gowda KA, Cartz L (1981) Heavy ion bombardment of monoclinic ThSiCXt, ThO2, and monazite. Radiat. Eff. Lett. 58: 1–3.
[22]
van Vlerken LE, Vyas TK, Amiji MM (2007) Poly(ethylene-glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24: 1405–14.
[23]
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, et al. (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25: 1341–51.
[24]
Hifumi H, Yamaoka S, Tanimoto A, Akatsu T, Shindo Y, et al. (2009) Dextran coated gadolinium phosphate nanoparticles for magnetic resonance tumor imaging. J. Mater. Chem. 19: 6393–7.
[25]
Kolsky KL, Mausner LF (1993) Production of no-carrier-added gold-199 for gold cluster-labeled antibodies. Appl. Radiat. Isot. 44: 553–60.
[26]
Buissette V, Giaume D, Gacoin T, Boilot JP (2006) Aqueous routes to lanthanide-doped oxide nanophosphors. J. Mater. Chem. 16: 529–39.
Woodward J, Kennel SJ, Stuckey A, Osborne D (2011) Wall J, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconj. Chem 22: 766–76.
[29]
Woodward JD, Kennel SJ, Mirzadeh S, Dai S, Wall JS, et al. (2008) In vivo SPECT/CT imaging and biodistribution using radioactive Cd125mTe/ZnS nanoparticles. Nanotechnology 18: 175103.
[30]
Kennel SJ, Huang Y, Zeng WB, Stuckey A, Wall J (2010) Kinetics of vascular targeted monoclonal antibody. Curr. Drug Deliv. 7: 428.
[31]
Kennel SJ, Woodward J D, Rondinone A J, Wall J, Huang Y, et al. (2008) The fate of MAb-targeted Cd(125mTe/ZnS) nanoparticles in vivo. Nucl. Med. Biol. 35: 501–14.
[32]
Vanrooijen N (1989) The liposome-mediated macrophage 'suicide' technique. J. Immunol. Methods 124: 1–6.
[33]
Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, et al. (2006) Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia. Immunol. 176: 6443–53.
[34]
Burdick MJ, Sartor O (2010) Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. Drug Discov. Today Ther. Strateg. 7: 23–9.
[35]
Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, et al. (2005) Efforts to control the errant products of a targeted in vivo generator. Cancer Res. 65: 4888–95.
[36]
Mirzadeh S, Kumar K, Gansow OA (1993) The chemical fate of 212Bi-DOTA formed by beta-decay of 212Pb(DOTA)2. Radiochim. Acta 60: 1–10.
